» Articles » PMID: 36551712

Correlation Between DNA Methylation and Cell Proliferation Identifies New Candidate Predictive Markers in Meningioma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Dec 23
PMID 36551712
Authors
Affiliations
Soon will be listed here.
Abstract

Meningiomas are the most common primary tumors of the central nervous system. Based on the 2021 WHO classification, they are classified into three grades reflecting recurrence risk and aggressiveness. However, the WHO's histopathological criteria defining these grades are somewhat subjective. Together with reliable immunohistochemical proliferation indices, other molecular markers such as those studied with genome-wide epigenetics promise to revamp the current prognostic classification. In this study, 48 meningiomas of various grades were randomly included and explored for DNA methylation with the Infinium MethylationEPIC microarray over 850k CpG sites. We conducted differential and correlative analyses on grade and several proliferation indices and markers, such as mitotic index and Ki-67 or MCM6 immunohistochemistry. We also set up Cox proportional hazard models for extensive associations between CpG methylation and survival. We identified loci highly correlated with cell growth and a targeted methylation signature of regulatory regions persistently associated with proliferation, grade, and survival. Candidate genes under the control of these regions include , , , , , , and --, i.e., the protocadherin gene clusters. This study highlights the crucial role played by epigenetic mechanisms in shaping dysregulated cellular proliferation and provides potential biomarkers bearing prognostic and therapeutic value for the clinical management of meningioma.

Citing Articles

MicroRNAs miR-16 and miR-519 control meningioma cell proliferation overlapping transcriptomic programs shared with the RNA-binding protein HuR.

Hergalant S, Casse J, Oussalah A, Houlgatte R, Helle D, Rech F Front Oncol. 2023; 13:1158773.

PMID: 37601663 PMC: 10433742. DOI: 10.3389/fonc.2023.1158773.


DNA methylation meningioma biomarkers: attributes and limitations.

Li Z, Gao Y, Zhang J, Han L, Zhao H Front Mol Neurosci. 2023; 16:1182759.

PMID: 37492524 PMC: 10365284. DOI: 10.3389/fnmol.2023.1182759.


A High MCM6 Proliferative Index in Atypical Meningioma Is Associated with Shorter Progression Free and Overall Survivals.

Gauchotte G, Bedel C, Lardenois E, Hergalant S, Cuglietta L, Pflaum R Cancers (Basel). 2023; 15(2).

PMID: 36672484 PMC: 9857276. DOI: 10.3390/cancers15020535.

References
1.
Jiang Y, Prabakaran I, Wan F, Mitra N, Furstenau D, Hung R . Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ. Biomark Res. 2015; 2:22. PMC: 4362647. DOI: 10.1186/2050-7771-2-22. View

2.
Paramasivam N, Hubschmann D, Toprak U, Ishaque N, Neidert M, Schrimpf D . Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol. 2019; 138(2):295-308. DOI: 10.1007/s00401-019-02008-w. View

3.
Jiang L, Zhou J, Zhong D, Zhou Y, Wu W, Zhao Z . Overexpression of SMC4 activates TGFβ/Smad signaling and promotes aggressive phenotype in glioma cells. Oncogenesis. 2017; 6(3):e301. PMC: 5533949. DOI: 10.1038/oncsis.2017.8. View

4.
Bozza W, Zhang Y, Hallett K, Rosado L, Zhang B . RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression. Oncotarget. 2015; 6(32):32723-36. PMC: 4741725. DOI: 10.18632/oncotarget.5416. View

5.
Lorenzo-Martin L, Fernandez-Parejo N, Menacho-Marquez M, Rodriguez-Fdez S, Robles-Valero J, Zumalave S . VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma. Nat Commun. 2020; 11(1):4788. PMC: 7508832. DOI: 10.1038/s41467-020-18524-3. View